Aripiprazole Tablet
Product Images NDC 50090-6063

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50090-6063). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Aripiprazole Figure 1)

A horizontal bar chart titled 'Effect of Other Drugs on Aripiprazole' shows fold change and 90% confidence intervals for aripiprazole pharmacokinetics. It plots changes in AUC and Cmax relative to reference without interacting drug for various inhibitors, inducers, gastric acid blockers, and other drugs including ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

FDA Label Image

Figure 2 (Aripiprazole Figure 2)

A chart depicting the effect of other drugs on aripiprazole pharmacokinetics, showing dehydro-aripiprazole fold change and 90% confidence intervals. The x-axis represents change relative to reference without interacting drug, while the y-axis lists CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs, with their impact on AUC and Cmax values displayed as data points with error bars.*

FDA Label Image

Figure 3 (Aripiprazole Figure 3)

A horizontal bar chart titled 'Effect of aripiprazole on Other Drugs' showing the fold change and 90% confidence intervals for various pharmacokinetic parameters of CYP2D6, CYP2C9, 2C19 substrates, and other drugs such as omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The x-axis represents the change relative to reference (without interacting drug) with values ranging from 0.5 to 3.0. Data points indicate the fold changes in parameters like AUC and Cmax for these drugs when affected by aripiprazole.*

FDA Label Image

Figure 4 (Aripiprazole Figure 4)

A chart titled 'Aripiprazole Fold Change and 90% CI' showing pharmacokinetic changes in special populations relative to a reference. It plots AUC and Cmax fold changes for groups including CYP2D6 metabolizer types, gender, age, hepatic impairment levels, and severe renal impairment. The x-axis represents change relative to reference on a scale from 0.5 to 3.0, with error bars indicating confidence intervals for each population comparison.*

FDA Label Image

Figure 5 (Aripiprazole Figure 5)

A pharmacokinetic chart illustrating the fold change and 90% confidence intervals of dehydro-aripiprazole relative to a reference. The chart compares variables including CYP2D6 metabolizer status, gender, age, hepatic impairment, and severe renal impairment, with changes shown for AUC and Cmax values.*

FDA Label Image

Figure-6 (Aripiprazole Figure 6)

A line graph comparing the proportion of subjects with relapse over time from randomization between Aripiprazole and placebo groups. The x-axis represents days from randomization up to 182 days, and the y-axis shows the proportion with relapse from 0.0 to 1.0. Aripiprazole is represented by a blue solid line showing lower relapse proportions compared to the red dashed placebo line. Below the x-axis is a table of the number of subjects at risk over time for both groups.*

FDA Label Image

Figure-7 (Aripiprazole Figure 7)

A line graph comparing the proportion of relapse over days from randomization between Aripiprazole and placebo groups. The x-axis represents days from randomization up to 182 days, and the y-axis shows the proportion with relapse. Two lines are shown: a solid blue line for Aripiprazole and a dashed red line for placebo. The graph includes the number of subjects at risk at various time points along the x-axis.*

FDA Label Image

Figure-8 (Aripiprazole Figure 8)

A Kaplan-Meier curve chart showing the proportion of subjects with relapse over days from randomization. The chart compares ARIPIPRAZOLE (solid blue line) and placebo (dashed red line) groups, with the x-axis representing days and the y-axis showing the proportion with relapse. The number of subjects at risk is listed below the x-axis for each treatment group at multiple time points up to 364 days.*

FDA Label Image

Aripiprazole Chemical Structure (Aripiprazole Structure)

Chemical structure of aripiprazole depicting its molecular framework including dichlorophenyl, piperazine, and quinolinone groups connected by an ether and alkyl chain.*

FDA Label Image

Label Image (Lbl500906063)

Label for ARIPIPRAZOLE 20 mg oral tablets by A-S Medication Solutions, pack of 30 tablets. The label includes lot and product numbers, storage instructions at 77 degrees F, and a QR code linking to dosage and package insert information. The product NDC is 50090-6063.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.